Frenzel Thomas, Lawaczeck Rüdiger, Taupitz Matthias, Jost Gregor, Lohrke Jessica, Sieber Martin A, Pietsch Hubertus
From the *MR and CT Contrast Media Research, Bayer Healthcare AG; †Department of Physical and Theoretical Chemistry, Free University; ‡Department of Radiology, Charite-Universitätsmedizin Berlin, Campus Benjamin Franklin; and §Clinical Project Management General Medicine, Bayer Healthcare AG, Berlin, Germany.
Invest Radiol. 2015 Sep;50(9):671-8. doi: 10.1097/RLI.0000000000000193.
Over the last 120 years, the extensive advances in medical imaging allowed enhanced diagnosis and therapy of many diseases and thereby improved the quality of life of many patient generations. From the beginning, all technical solutions and imaging procedures were combined with dedicated pharmaceutical developments of contrast media, to further enhance the visualization of morphology and physiology. This symbiosis of imaging hardware and contrast media development was of high importance for the development of modern clinical radiology. Today, all available clinically approved contrast media fulfill the highest requirements for clinical safety and efficacy. All new concepts to increase the efficacy of contrast media have also to consider the high clinical safety standards and cost of goods of current marketed contrast media. Nevertheless, diagnostic imaging will contribute significantly to the progresses in medicine, and new contrast media developments are mandatory to address the medical needs of the future.
在过去的120年里,医学成像的广泛进步使得许多疾病的诊断和治疗得到改善,从而提高了几代患者的生活质量。从一开始,所有技术解决方案和成像程序都与造影剂的专门药物研发相结合,以进一步增强形态学和生理学的可视化。成像硬件与造影剂开发的这种共生关系对现代临床放射学的发展至关重要。如今,所有临床批准的造影剂都满足临床安全性和有效性的最高要求。所有提高造影剂功效的新概念也必须考虑当前市售造影剂的高临床安全标准和商品成本。尽管如此,诊断成像将对医学进步做出重大贡献,新的造影剂开发对于满足未来的医疗需求是必不可少的。